In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Leslie Citrome
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Leslie Citrome

RESEARCHER INFORMATION
First Name:Leslie
Last Name:Citrome
Title:Dr.
Advanced Degrees:MD, MPH
City:Pomona
State/Province:NY
Zip/Postal Code:10970
Country/Territory:U.S.A.
Email Address:nntman@gmail.com
Disclosure:
(view policy) 
 
View all comments by Leslie Citrome
Clinical Interests:
Schizophrenia
Research Focus:
Pharmacology, Epidemiology
Work Sector(s):
University, Private practice
Reasearcher Bio
Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility located at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York. After nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm.

Dr. Citrome graduated from the McGill University Faculty of Medicine and completed a Residency and Chief Residency in Psychiatry at the New York University School of Medicine. He went on to complete a Masters in Public Health from the Columbia University School of Public Health.

Dr. Citrome’s primary research interests have centered on psychopharmacologic approaches to schizophrenia, management of treatment-refractory schizophrenia, and the management of aggressive and violent behavior. He is the author or co-author of over 400 research reports, reviews, chapters and abstracts in the scientific literature, is the Associate Editor for Psychiatry for the International Journal of Clinical Practice, serves on the editorial board of 6 other medical journals, reviews for over 50 journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.
Top Papers
1. Citrome L, Jaffe A, Levine J, Martello D: Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004, Psychiatric Services 57(8):1132-1139, 2006
2. Citrome L, Jaffe A, Levine J: Dosing of Second-Generation Antipsychotic Medication in a State Hospital System. Journal of Clinical Psychopharmacology 25(4):388-391, 2005
3. Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chakos M, Lieberman J: Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients with Schizophrenia. Psychiatric Services 52(11): 1510-1514, 2001
4. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman J: Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients with Chronic Schizophrenia and Schizoaffective Disorder. American Journal of Psychiatry 159(2):255-262, 2002
5. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Lieberman JA: Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Treatment-Resistant Patients with Schizophrenia and Schizoaffective Disorder. American Journal of Psychiatry 159(6):1018-1028, 2002
6. Krakowski M, Czobor P, Citrome L, Bark N, Cooper T: Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives General Psychiatry 63(6):622-629, 2006
7. Citrome L, Volavka J: Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence, Harvard Review of Psychiatry 10:280-291, 2002
What are the top three papers (not yours) you have read recently?
1. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW.Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).Arch Gen Psychiatry. 2006 Oct;63(10):1079-87.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23.
3. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C.Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.CNS Drugs. 2006;20(5):389-409.



Research Participants
Collaborators
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright